Genmab A/S (GMAB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Genmab A/S (GMAB) closed at USD 36.89 on 2026-10-14, a change of +26.6 % over the past year, with a market capitalization of USD 23.26B.

Genmab A/S recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Genmab A/S key figures

Previous close

USD 36.89 (2026-10-14)

1-year change

+26.6 %

Market cap

USD 23.26B

Enterprise value

USD 26.34B

P/E ratio (trailing)

29.78

P/E ratio (forward)

24.96

EPS (trailing)

1.27

EPS (forward)

1.52

PEG ratio

4.65

Price to book

3.79

Revenue growth

24.9 %

Earnings growth

-9.4 %

Dividend per share (trailing)

0.00

Short ratio

2.65

Employees

3,119

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Genmab A/S and compare it with other stocks.